ContraFect Beheer

Beheer criteriumcontroles 3/4

De CEO ContraFect is Mike Messinger, benoemd in Nov2018, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 957.21K, bestaande uit 42.9% salaris en 57.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde $ 1.42. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 9.7 jaar.

Belangrijke informatie

Mike Messinger

Algemeen directeur

US$957.2k

Totale compensatie

Percentage CEO-salaris	42.9%
Dienstverband CEO	5.1yrs
Eigendom CEO	0.0002%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	9.7yrs

Recente managementupdates

Recent updates

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

Mar 09

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Jan 15

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Nov 24

Contrafect EPS beats by $0.16

Nov 13

Analyse CEO-vergoeding

Hoe is Mike Messinger's beloning veranderd ten opzichte van ContraFect's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$36m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$957k	US$410k	-US$65m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$35m
Dec 31 2021	US$883k	US$389k	-US$20m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$1m	US$374k	-US$28m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$41m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	n/a	n/a	-US$13m
Sep 30 2019	n/a	n/a	US$3m
Jun 30 2019	n/a	n/a	US$4m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	n/a	n/a	-US$38m
Sep 30 2018	n/a	n/a	-US$48m
Jun 30 2018	n/a	n/a	-US$46m
Mar 31 2018	n/a	n/a	-US$28m
Dec 31 2017	US$616k	US$315k	-US$16m

Compensatie versus markt: De totale vergoeding ($USD 957.21K ) Mike } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 642.87K ).

Compensatie versus inkomsten: De vergoeding van Mike is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mike Messinger (48 yo)

5.1yrs

Tenure

US$957,211

Compensatie

Mr. Michael Messinger, C.P.A., also known as Mike, is President and Chief Executive Officer at ContraFect Corporation since November 15, 2023. He has been Chief Financial Officer of ContraFect Corp. since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Messinger	CEO, President	5.1yrs	US$957.21k	0.00021% $ 1.4
Natalie Bogdanos	General Counsel	9.3yrs	US$844.90k	0.000010% $ 0.07
Matthew Salamone	Vice President of Human Resources	1.8yrs	geen gegevens	geen gegevens
Gary Woodnutt	Senior Vice President of Translational Sciences & Preclinical Development	2.5yrs	geen gegevens	geen gegevens
William Nichols	Interim Chief Medical Officer	1.3yrs	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CFRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sol Barer	Lead Independent Director	12.7yrs	US$176.04k	0.0095% $ 64.4
Steven Gilman	Vice Chairman	8.6yrs	US$160.54k	0.00024% $ 1.6
Lishan Aklog	Independent Director	3.5yrs	US$150.54k	0% $ 0
Roger Pomerantz	Chairman	9.7yrs	US$2.23m	0.000010% $ 0.07
Michael Otto	Independent Director	9.7yrs	US$160.04k	0.000090% $ 0.6
Leon Smith	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Palese	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Adolfo Garcia-Sastre	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Vincent Fischetti	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Cary Sucoff	Independent Director	13.6yrs	US$155.54k	0.00072% $ 4.9
David Low	Independent Director	9.7yrs	US$165.04k	0.0043% $ 29.3
Daniel Capon	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

9.7yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CFRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.7 jaar).

ContraFect Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

ContraFect Corporation Announces Chief Executive Officer Changes

Contrafect Corporation Announces Resignation of Cara Cassino as Chief Medical Officer and Executive Vice President of Research and Development

ContraFect Corporation, Annual General Meeting, May 17, 2022

ContraFect Corporation Appoints Jane F. Barlow to its Board of Directors

Recent updates

ContraFect Corporation Filed for Bankruptcy

ContraFect Corporation Announces Chief Executive Officer Changes

ContraFect Receives Determination Letter from the Nasdaq Hearings Advisor to Delist its Common Stock from the Nasdaq Capital Market

ContraFect Receives Non Compliance Notice from Nasdaq

Nasdaq Determines to Delist ContraFect's Common Stock from The Nasdaq Capital Market Due to Non-Compliance with Minimum Stockholders' Equity Requirement

ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens

ContraFect Announces Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Nasdaq Determines to Deny ContraFect's Request for Continued Listing on the Nasdaq Capital Market

ContraFect Corporation Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

ContraFect Corporation Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Price target decreased to US$2.00

ContraFect Receives Non-Compliance Letter from Nasdaq

Contrafect Corporation Announces Resignation of Cara Cassino as Chief Medical Officer and Executive Vice President of Research and Development

Contrafect GAAP EPS of -$0.46 misses by $0.13

No longer forecast to breakeven

Contrafect Announces Independent Dsmb Recommends Exebacase Phase 3 Disrupt Study Be Stopped for Futility Following Interim Analysis

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$13.00

ContraFect Corporation, Annual General Meeting, May 17, 2022

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Price target decreased to US$15.90

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

ContraFect Corporation Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

New 90-day low: US$4.81

ContraFect Corporation Appoints Jane F. Barlow to its Board of Directors

New 90-day low: US$4.96

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

New 90-day low: US$5.09

New 90-day high: US$5.87

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Contrafect EPS beats by $0.16

Analysts update estimates

ContraFect Corporation announced that it has received $3 million in funding from Pfizer Inc.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd